Sign In
Buy PFE
$26.04
+0.350 (+1.36%)
At Close: Jun 05, 2026
SGEN Stock Alert: Pfizer Buys Seagen in GIANT $43 Billion Deal
11:15am, Monday, 13'th Mar 2023
Seagen (NASDAQ: SGEN ) stock is taking off on Monday as investors react to an acquisition deal with Pfizer (NYSE: PFE ). Pfizer is acquiring Seagen for $43 billion in cash.
Pfizer Officially Nabs Seagen For $43 Billion; Provention Soars On Sanofi Deal
09:17am, Monday, 13'th Mar 2023
Pfizer will buy Seagen for roughly $43 billion, and Sanofi will buy Provention for $2.9 billion. SGEN stock and PRVB stock soared.
Pfizer to purchase Seagen in $43 billion all-cash deal, cancer biotech's stock pops 20%
07:04am, Monday, 13'th Mar 2023
Pfizer Inc. PFE, -0.18% plans to acquire cancer biotechnology company Seagen Inc. SGEN, -0.59% in a deal with a $43 billion enterprise value, the companies announced Monday morning. Pfizer intends to
This Logistics Company Appears To Be A Better Pick Over Pfizer Stock
07:00am, Monday, 13'th Mar 2023
We believe that FedEx stock (NYSE: FDX) is a better pick than the pharmaceutical giant Pfizer stock (NYSE: PFE), given its better prospects.
The 7 Most Undervalued Stocks to Buy in March 2023
03:11pm, Sunday, 12'th Mar 2023
The equities market continues to be incredibly volatile. Investors were optimistic following a robust rally in Jan.; all major U.S. indices are down since then.
7 Compelling Investment Opportunities for Beginning Investors in Their 30s
02:44pm, Sunday, 12'th Mar 2023
Although financial advisors often urge the public to start saving for retirement as soon as possible, the realities of life mean that several people in their 30s must consider certain investment oppor
A new migraine medication is coming this summer — and it promises relief in just 15 minutes
12:50pm, Saturday, 11'th Mar 2023
The Food and Drug Administration approved Zavzpret, a nasal spray from Pfizer, on Friday. The medication is expected to hit shelves this July.
Pfizer wins FDA approval for its migraine nasal spray
06:54am, Friday, 10'th Mar 2023
Pfizer Inc. PFE, -1.65% said Friday the U.S. Food and Drug Administration has approved its migraine nasal spray Zavzpret. The treatment is the first and only calcitonin gene-related peptide (CGRP) rec
Pfizer Is Targeting an Acquisition That Could Be a Game Changer for Its Business
09:37am, Thursday, 09'th Mar 2023
Pfizer's business isn't all that diverse outside of COVID-19 revenue. Adding more products to its portfolio can make Pfizer a safer buy.
7 Most Undervalued Stocks to Buy for 2023
08:46pm, Wednesday, 08'th Mar 2023
The stock market continues to be volatile. After a strong rally in January, all major U.S. indices retreated in February, with the benchmark S&P 500 falling 2.6% during the month.
7 Stocks at 52-Week Lows and Highly Attractive From Here
04:05pm, Wednesday, 08'th Mar 2023
Although public companies that suffer staggering losses often do so for good reason, sometimes, it might be worthwhile to take a shot with stocks at 52-week lows. Some of the justification comes down
3 Must-Buy Income Champs as Fed Rates Head to 5%
08:33am, Wednesday, 08'th Mar 2023
When the U.S. central bank raises interest rates and keeps them elevated, investors should position toward must-buy income stocks to buy. Risk-free cash invested in various funds will pay close to the
U.S. Wide-Moat Stocks On Sale - The March 2023 Heat Map
08:09am, Wednesday, 08'th Mar 2023 Seeking Alpha
We are only interested in those targets that are attractively valued in historical comparison. Click here for our 3-step process that focuses on wide-moat stocks.
Lilly's (LLY) Verzenio Gets FDA Nod for Expanded Breast Cancer
04:00pm, Tuesday, 07'th Mar 2023 Zacks Investment Research
Eli Lilly (LLY) announces FDA approval of label expansion of Verzenio (abemaciclib), in combination with endocrine therapy, for treating HR+, HER2-, node-positive and high-risk early breast cancer.
Pfizer (PFE) or GSK: Who Will Get the First FDA Nod for RSV Jab?
03:33pm, Tuesday, 07'th Mar 2023 Zacks Investment Research
An FDA advisory committee recommended approving Pfizer's (PFE) and GSK's respective RSV vaccines for older adults. Currently, there are no RSV vaccines anywhere in the world.
